Efficacy and safety of Cinainu in paediatric alopecia areata: an international, double-blind, randomized, placebo-controlled, phase II/III trial
In this study, Cinainu showed efficacy, safety and sustained benefits during follow-up in children and adolescents with moderate-to-severe AA, a population with significant unmet needs.
Authors
- Julien Guiraud (ORCID: https://orcid.org/0000-0003-1284-7949)
- Ulrike Blume‐Peytavi (ORCID: https://orcid.org/0000-0003-3528-3752)
- Bianca Maria Piraccini (ORCID: https://orcid.org/0000-0001-6537-9689)
- B.N. Mukherjee (ORCID: https://orcid.org/0000-0002-7465-9225)
- Saad Harti (ORCID: https://orcid.org/0000-0002-9328-1256)
- A Guichard (ORCID: https://orcid.org/0000-0002-1034-8815)
- Pascal Reygagne (ORCID: https://orcid.org/0000-0002-6062-2122)
- Jiawei Liu (ORCID: https://orcid.org/0000-0002-0852-4779)
- William Pralong
Institutions
- Legacy Health (US)
- Clinical Research Center for Hair and Skin Science (DE)
- Azienda USL di Bologna (IT)
- Hôpital Saint-Louis (FR)
- Tata Consultancy Services (India) (IN)
- Versar (United States) (US)
- University of Bologna (IT)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1093/bjd/ljaf279
- Citations
- 3
- Primary Topic
- Hair Growth and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 5.51
Funders
- Eli Lilly and Company
- Pfizer
- Sanofi
- Regeneron Pharmaceuticals
- Les Laboratories Pierre Fabre
- Galderma